Viral Vector Technology Services

1. Platform Overview

Viral vectors are indispensable core tools in gene function research, gene therapy, cell therapy, and vaccine development. After decades of engineering refinement, viral vectors represented by AAV, lentivirus, and adenovirus have evolved beyond laboratory instruments to become central components of clinical-grade therapeutic products — more than 30 gene therapy drugs utilizing viral vectors as their delivery core have received regulatory approval worldwide.

We specialize in the engineering design, scalable manufacturing, and quality control of viral vectors, with deep expertise across lentiviral, AAV, adenoviral, and novel virus-like particle technologies. Backed by a comprehensive service portfolio spanning seven vector platforms, we provide end-to-end CRO/CDMO services — from plasmid construction through GMP batch release — for academic institutions, biotechnology companies, and multinational pharmaceutical enterprises. A complete Certificate of Analysis (COA) is issued for every batch, ensuring full traceability and data integrity.

2. Core Capabilities

Viral Vector Design & Plasmid Engineering

Serotype/pseudotype selection, ITR/LTR optimization, and promoter engineering, supported by molecular cloning and sequencing verification.

Scalable Manufacturing & Purification

HEK293T-based production platform with ultracentrifugation and chromatography-based purification processes; scalable from research-grade to GMP-grade outputs.

Quality Control Release & Batch Documentation

Comprehensive testing including physical/infectious titer, endotoxin, sterility, RCL, and residual HCD; complete COA and Batch Manufacturing Record (BMR) documentation.

Capsid Engineering & Custom Modification

Directed evolution, peptide insertion, and pseudotyping; supporting custom development of target specificity and immune evasion capabilities.

3. Our Advantages

◆   Dedicated Viral Vector Expertise   

Deep process knowledge across all seven vector platforms: established solutions for AAV full-to-empty ratio optimization and high-functional-titer lentiviral manufacturing.

◆   GMP Quality System   

Fully traceable raw materials and complete batch records (BMR); supports IND filing and preparation of FDA/EMA regulatory data packages.

◆   Flexible Manufacturing Scale   

From small-scale research samples to GMP clinical batches, production capacity is dynamically matched to project stage.

◆   Cross-Platform Vector Strategy   

Single projects can leverage multi-platform integrated design (e.g., IDLV-mediated editing combined with AAV long-term expression), with consultative vector strategy recommendations provided.

4. Seven Technology Platforms at a Glance

The choice of viral vector directly determines delivery efficiency, safety, and manufacturability. The following is a concise overview of the core technical characteristics of our seven viral vector and nanoparticle platforms for selection guidance:

5.   Standard Service Workflow

• Requirements Consultation — Complimentary feasibility assessment to define target gene, intended use, and quality grade requirements.

• Contract Execution — Finalization of technical specifications, delivery standards, milestone schedule, and confidentiality agreement.

• Production Execution — Plasmid construction → manufacturing → purification, with full process documentation and in-process testing throughout.

• Quality Release — Comprehensive QC testing, data review, and issuance of COA and batch records.

• Delivery & Support — Cold-chain shipping with usage recommendations; optional downstream functional verification available.